In a mouse model of hereditary transthyretin amyloidosis, liraglutide directly bound to transthyretin and reduced its deposits in brain tissue, but did not improve any cardiovascular outcomes compared to placebo.
Direct binding to transthyretin confirmedLiraglutide was shown to have high affinity for and directly bind to transthyretin protein, reducing its accumulation in brain tissue of amyloidosis mice — a previously unknown interaction.
What the researchers found
High-throughput screening and microscale thermophoresis confirmed that liraglutide has high affinity for and directly binds to transthyretin (TTR) protein. In humanized ATTRv mice carrying the Val50Met mutation, 28 days of liraglutide treatment (0.3 mg/kg/day) significantly decreased TTR protein content in brain tissue compared to placebo.
However, cardiovascular endpoints showed no benefit. Plasma BNP (heart failure marker), cardiac fibrosis markers (Col1a1 and TGFβ1 expression), and pathological measures (right ventricular collagen percentage, ventricular septum thickness, left ventricular wall thickness, and left ventricular internal diameter) were all statistically comparable between liraglutide and placebo groups.
Why it matters
Transthyretin amyloidosis is a serious and progressive disease with limited treatment options. The finding that a widely available GLP-1 receptor agonist can directly bind transthyretin and reduce its brain accumulation is novel and opens a potential new therapeutic avenue — particularly for the neurological aspects of the disease. The lack of cardiac benefit in this short study doesn't rule out longer-term effects and highlights the need for further research.
How the study worked
Researchers first used high-throughput screening to identify liraglutide's drug targets and microscale thermophoresis to confirm direct binding to TTR. They then constructed humanized mouse models: RBP4/TTR (normal) and RBP4/TTR-Val50Met (ATTRv disease) mice. Mice were treated with liraglutide (0.3 mg/kg/day) or placebo for 28 days. Outcomes were assessed using glucose tolerance tests, plasma BNP measurement, western blot, ELISA, RT-qPCR, and pathological tissue staining.
What this study cannot tell us
This was a short-term (28-day) animal study using genetically engineered mice, which may not fully replicate human disease progression. The sample size of mice is not specified in the abstract. The lack of cardiac benefit could be due to the short treatment duration or the dose used. The humanized mouse model, while more relevant than standard mice, still has inherent differences from human disease. Only one dose level was tested.
How to read the evidence
This is an early-stage preclinical study in genetically engineered mice. While the binding confirmation and brain tissue results are promising, this represents exploratory animal research with no human data, placing it at a preliminary evidence level.
When this study was published
Published in 2025, this is very recent research exploring a novel application of liraglutide. As an early preclinical study, human clinical investigations would still be years away.
The bigger picture
GLP-1 receptor agonists continue to reveal unexpected therapeutic effects beyond diabetes and weight management. The discovery that liraglutide directly binds transthyretin adds to the growing list of off-target interactions for this drug class. If the brain-protective effects translate to humans, it could offer a new approach to the neurological complications of hereditary amyloidosis — a disease area where treatment options remain limited.
Questions still open
- Would longer treatment duration with liraglutide eventually show cardiovascular benefits in transthyretin amyloidosis?
- Could the brain TTR reduction translate to meaningful neurological improvements in human hereditary amyloidosis patients?
- Do other GLP-1 receptor agonists like semaglutide also bind transthyretin, and could they be more potent?
Common questions
Can liraglutide treat transthyretin amyloidosis?
Why is it significant that liraglutide binds to transthyretin?
Read the original research
Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models.
International journal of medical sciences, 22(13), 3229-3241
Citation
Zhang, Mengqing; Li, Zonglin; Cai, Xiaoling; Lv, Fang; Wen, Xin; Guo, Chengcheng; Lin, Chu; Ji, Linong. (2025). Cardiovascular and brain effects of liraglutide in transthyretin amyloidosis (ATTR) mice models.. International journal of medical sciences, 22(13), 3229-3241. https://doi.org/10.7150/ijms.112264